|
業務類別
|
Biotechnology |
|
業務概覽
|
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF). |
| 公司地址
| 945 Concord Street, Suite 1217, Framingham, MA, USA, 01701 |
| 電話號碼
| +1 888 355-4440 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.pulmatrix.com |
| 員工數量
| 2 |
| Mr. Peter Ludlum |
Interim Chief Executive Officer, Interim Chief Financial Officer and Principal Accounting Officer |
-- |
26/02/2026 |
|
|
| Dr. Christopher Cabell, F.A.C.C.,M.D.,M.H.S. |
Independent Director |
26/02/2026 |
| Mr. Anand Varadan |
Independent Director |
26/02/2026 |
| Dr. Richard P. Batycky, PhD |
Independent Director |
26/02/2026 |
| Mr. Todd Bazemore |
Independent Director |
26/02/2026 |
| Mr. Michael J. Higgins |
Chairman of the Board |
26/02/2026 |
|
|
|
|
